Roshanak Derakhshandeh, MD
Pathology · Washington
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Medstar Medical Group II LLC · 3,726 clinicians in this group
Looking this up.
Hospitals listed: Medstar Georgetown University Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Derakhshandeh’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A172278 · Delinquent
Licence status: Delinquent · since 2021 · expires 2023-04-30 · Iran University of Medical Sciences and Health Services.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Medstar Georgetown University HospitalWashington, DCAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of MedStar Health, which runs 10 hospitals in 2 statesHome of Georgetown Lombardi Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.26 (0.78 to 1.75) · 7,465 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.125, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.391, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.179, Oct 2024 – Sep 2025
See every measure and the patient survey for Medstar Georgetown University Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.26 (0.78 to 1.75) · 7,465 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.125 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.391 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.179 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.91 (0.09 to 1.72) · 3,048 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.13 (0.9 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.6 (140.59 to 214.61) · 263 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 33 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 166 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.6 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 231 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,748 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.32) · 8,632 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 9,112 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (3.03 to 6.05) · 3,698 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.32 to 3.13) · 2,153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (1.49 to 3.7) · 3,499 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.87 (3.27 to 12.46) · 2,168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.06 (1.41 to 6.7) · 2,143 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.37 (0.02 to 2.72) · 1,506 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 53 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.867 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.162 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.3 · 192 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.5 · 265 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 302 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.8 (4.5 to 7.4) · 629 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (8.3 to 12.1) · 629 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (10.3 to 16.4) · 2,279 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 775 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,947 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 57% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$54,513
Medicare paid this office $54,513 for 460 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 326 | $18,459 | $30 |
| Pathology examination of tissue using a microscope, moderately high complexity | 84 | $11,202 | $67 |
| Special stained specimen slides to examine tissue, each additional procedure | 97 | $9,097 | $23 |
| Special stained specimen slides to examine tissue, initial procedure | 150 | $5,249 | $28 |
| Pathology examination of tissue using a microscope, high complexity | 26 | $3,826 | $120 |
See all 13 services
| Pathology examination of tissue using a microscope, intermediate complexity | 326 | $18,459 | $30 |
| Pathology examination of tissue using a microscope, moderately high complexity | 84 | $11,202 | $67 |
| Special stained specimen slides to examine tissue, each additional procedure | 97 | $9,097 | $23 |
| Special stained specimen slides to examine tissue, initial procedure | 150 | $5,249 | $28 |
| Pathology examination of tissue using a microscope, high complexity | 26 | $3,826 | $120 |
| Pathology examination of specimen during surgery, first tissue block | 15 | $1,744 | $51 |
| Microscopic genetic analysis of tumor, manual | 29 | $1,706 | $34 |
| Special stained specimen slides to identify organisms including interpretation and report | 25 | $725 | $22 |
| Pathology examination of tissue using a microscope, moderately low complexity | 40 | $494 | $9 |
| Preparation of tissue for examination by removing any calcium present | 34 | $480 | $10 |
| X-ray of surgical specimen | 14 | $232 | $13 |
| Pathology examination of tissue using a microscope | 11 | $63 | $6 |
| Pathology examination of tissue using a microscope, limited examination | 13 | $56 | $4 |
Who their Medicare patients are
460 Original Medicare patients in 2024. Average age 73 · Under 65 9% · 85 and older 9% · Women 50% · Also on Medicaid 13% · Health risk score 1.64. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Cancer 35% · Diabetes 33% · Coronary heart disease 32% · Chronic kidney disease 29% · Depression 19% · Heart failure 16% · Atrial fibrillation 15% · COPD 14% · Stroke 12% · Dementia 7%.
The office billed $216,608, Medicare allowed $69,438 and paid $54,513; for 1,699 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 460 | 1,699 | 73 | 1.64 | $216,608 | $54,513 |
| 2023 | 355 | 1,608 | 72 | 1.80 | $197,582 | $51,310 |
| 2022 | 273 | 1,033 | 72 | 1.95 | $124,991 | $33,906 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Pathology examination of tissue using a microscope, intermediate complexity | 255 | $15,671 | $30 |
| Special stained specimen slides to examine tissue, each additional procedure | 98 | $10,363 | $24 |
| Pathology examination of tissue using a microscope, moderately high complexity | 71 | $9,934 | $69 |
| Special stained specimen slides to examine tissue, initial procedure | 133 | $4,816 | $30 |
| Pathology examination of tissue using a microscope, high complexity | 21 | $2,846 | $124 |
| Microscopic genetic analysis of tumor, manual | 34 | $2,384 | $32 |
| Pathology examination of specimen during surgery, first tissue block | 19 | $2,123 | $53 |
| Special stained specimen slides to identify organisms including interpretation and report | 18 | $880 | $23 |
| Pathology examination of tissue using a microscope, moderately low complexity | 38 | $486 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $401 | $10 |
| Preparation of tissue for examination by removing any calcium present | 24 | $350 | $11 |
| X-ray of surgical specimen | 13 | $181 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 12 | $42 | $4 |
2022: 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 216 | $13,352 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 62 | $5,322 | $24 |
| Pathology examination of tissue using a microscope, moderately high complexity | 47 | $5,042 | $72 |
| Special stained specimen slides to examine tissue, initial procedure | 91 | $3,340 | $30 |
| Pathology examination of tissue using a microscope, high complexity | 18 | $2,529 | $126 |
| Microscopic genetic analysis of tumor, manual | 21 | $1,226 | $36 |
| Special stained specimen slides to identify organisms including interpretation and report | 24 | $776 | $23 |
| Preparation of tissue for examination by removing any calcium present | 24 | $382 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 26 | $370 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $296 | $11 |
Medicaid work
$1,996 in 2024
Medicaid paid $1,996 for 38 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 38 | $1,996 |
| 2024 | 38 | 1 | 13 | $1,996 |
| 2023 | 133 | 1 | 21 | $7,326 |
| 2022 | 31 | 1 | 16 | $722 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 133 | $7,326 |
2022
| TISSUE EXAM BY PATHOLOGIST | 31 | $722 |
Money from drug and device companies
$26 in 2023
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $26 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2023-04-24 | Keytruda | $26 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1215468780
- Licence
- CA A172278California A172278: Delinquent · expires 2023-04-30
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-03-25
- NPI last updated
- 2021-06-13
- NPI record certified
- 2021-06-13
This is when the NPI record was last certified, not a medical board exam.